|
|
|
|
|
Nadolol: profile and news
Ask the Clinician: Answers to Readers' Questions Feb 20, 2006 King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 ... Feb 28, 2006 Just see, before it catches you Dec 9, 2005 Pediatric Patients with Refractory Headache Respond to Zonisamide ... Oct 17, 2005 To: National Desk, Health and Consumer Reporter Mar 28, 2005 Lower-Cost Drugs Can Help Heart Patients Apr 1, 2005 Management of Hypertension in Older Persons Feb 21, 2005 BCBSNC Launches New Prescription Drug Savings Initiative Feb 17, 2005 Other information Indication For the treatment of arrhythmias, angina pectoris, and hypertension Pharmacology Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. Mechanism Of Action Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. Drug Category Sympatholytics; Antihypertensive Agents; Anti-Arrhythmia Agents; Adrenergic beta-Antagonists; ATC:C07AA12 Brand Names/Synonyms Anabet; CCRIS 1048; Corgard; Corzide; HSDB 6532; Nadolol; Nadolol [Usan:Ban:Inn:Jan]; Nadololum [Inn-Latin]; Solgol Dosage Forms Tablets (20 mg, 40 mg, 80 mg, 120 mg, and 160 mg) Absorption Absorption of nadolol after oral dosing is variable, averaging about 30 percent. Interactions Interactions for Nadolol: When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics. Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia; adjust dosage of antidiabetic drug accordingly. Catecholamine-depleting drugs (e.g., reserpine): additive effect; monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension). Response to Treatment for Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Chemical IUPAC Name 5-(2-hydroxy-3-tert-butylamino-propoxy)tetralin-2,3-diol Chemical Formula C17H27NO4 Half Life 14-24 hours Drug Type Approved Drug # Accession No APRD00301 CAS Registry Number 42200-33-9 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |